Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $57,542.40 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 2,368 shares of the stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total transaction of $57,542.40. Following the transaction, the chief financial officer now owns 37,270 shares of the company’s stock, valued at $905,661. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Houte Hans Van also recently made the following trade(s):

• On Monday, August 26th, Houte Hans Van sold 20,000 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.22, for a total transaction of $504,400.00.
• On Thursday, August 1st, Houte Hans Van sold 3,477 shares of Nurix Therapeutics stock. The stock was sold at an average price of $21.45, for a total value of $74,581.65.

Nurix Therapeutics Trading Up 2.1 %

Shares of NASDAQ NRIX opened at $24.58 on Friday. Nurix Therapeutics, Inc. has a 52-week low of $4.96 and a 52-week high of $27.60. The stock has a 50 day moving average price of $24.21 and a 200 day moving average price of $20.20.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.67). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. The business had revenue of $12.59 million during the quarter, compared to analyst estimates of $13.85 million. Research analysts predict that Nurix Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Oppenheimer upped their price objective on Nurix Therapeutics from $27.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, September 4th. HC Wainwright raised their price target on Nurix Therapeutics from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Robert W. Baird assumed coverage on shares of Nurix Therapeutics in a research report on Friday, September 6th. They set an “outperform” rating and a $26.00 price objective on the stock. Truist Financial initiated coverage on shares of Nurix Therapeutics in a report on Wednesday, July 31st. They issued a “buy” rating and a $36.00 target price for the company. Finally, Jefferies Financial Group began coverage on shares of Nurix Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $41.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $29.40.

Institutional Trading of Nurix Therapeutics

A number of hedge funds have recently added to or reduced their stakes in NRIX. Amalgamated Bank increased its position in Nurix Therapeutics by 30.6% during the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after purchasing an additional 511 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of Nurix Therapeutics by 77.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,388 shares of the company’s stock valued at $278,000 after purchasing an additional 5,419 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Nurix Therapeutics by 31.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after buying an additional 559 shares during the period. International Assets Investment Management LLC raised its stake in Nurix Therapeutics by 1,098.4% in the third quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock worth $101,000 after buying an additional 4,119 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new stake in Nurix Therapeutics during the third quarter worth $3,152,000.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.